XLV holds the healthcare sector of the S&P 500, spanning pharmaceutical giants, managed care companies, medical device manufacturers, biotech firms and healthcare services providers. The portfolio is typically led by UnitedHealth Group, Eli Lilly, Johnson & Johnson, AbbVie and Merck. Healthcare combines two characteristics that are rarely available in a single sector: defensive demand — people need medical care regardless of economic conditions — and long-term structural growth from aging demographics and medical innovation. This makes XLV one of the most popular sector tilts for investors seeking to reduce portfolio cyclicality without sacrificing growth potential. Drug pricing regulatory risk is the primary political overhang, and election cycles can create volatility in healthcare stocks as policy proposals emerge. The GLP-1 weight loss drug category has been a significant recent earnings driver for certain holdings. For investors, XLV is an excellent core holding that provides genuine defensive characteristics without the yield-dependence of utilities, and benefits from a decades-long demographic tailwind that makes the structural case for healthcare demand straightforward and durable.
